comparing cardiovascular and kidney outcomes with tirzepatide vs. glp-1 agonists Bridging the gap between GLP1-receptor outcomes: evidence for the role of | Cardiovascular Diabetology Kidney Outcomes With Glucagon-Like Peptide-1

[DOI] [PMC free article] [PubMed] [Google Scholar] 192.Bolli GB, Munteanu M, Dotsenko S, Niemoeller E, Boka G, Wu Y, Hanefeld M

Public and private payers are gradually recognizing obesity as a chronic disease, improving affordability for eligible patients and encouraging physicians to prescribe GLP-1 therapies

Again, as in the case of the sitagliptin-treated HIP rats, there was no discernable clinical manifestation of the low-grade pancreatitis induced by exenatide, with the rats in no apparent pain

To the best of our knowledge, this meta-analysis is the first to evaluate the effects and safety of SGLT2i and GLP-1RAs as first-line therapy for T2DM with low cardiovascular risk

Top 20 Companies Leading the Global Glucagon-Like Peptide-1 agonists Market Novo Nordisk Eli Lilly and Company Sanofi AstraZeneca Pfizer Inc

This may help explain why GLP-1 drugs are so effective in helping some people with obesity lose weight